Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lonza GroupXSWX:LONN -1.01%83 Equity-to-Asset is 0.45 as of Jun. 2026, which is 4% below its 10-year median of 0.47. GuruFocus rates XSWX:LONN with a GF Score™ of 83/100 and a GF Value™ of CHF579.95 (Fairly Valued). The stock has 4 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Lonza Group ranks worse than 69.05% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lonza Group's Total Stockholders Equity for the quarter that ended in Jun. 2026 was CHF8,120 Mil. Lonza Group's Total Assets for the quarter that ended in Jun. 2026 was CHF18,258 Mil.
Therefore, Lonza Group's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.45.
The historical rank and industry rank for Lonza Group's Equity-to-Asset or its related term are showing as below:
XSWX:LONN'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34 Med: 0.47 Max: 0.61
Current: 0.45
During the past 13 years, the highest Equity to Asset Ratio of Lonza Group was 0.61. The lowest was 0.34. And the median was 0.47.
XSWX:LONN's Equity-to-Asset is ranked worse than 69.05% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.595
vs XSWX:LONN: 0.45
Lonza Group (XSWX:LONN) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lonza Group Equity-to-Asset Related Terms
Lonza Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Lonza Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LONN vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Lonza Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lonza Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lonza Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (XSWX:LONN) has a Equity-to-Asset of 0.45 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lonza Group and its competitors. This is near median its historical median of 0.47. Over the past decade, Lonza Group's Equity-to-Asset has ranged from 0.34 to 0.61. According to the industry distribution chart, Lonza Group ranks #145 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 69%.
Is Lonza Group's Equity-to-Asset too high?
Lonza Group's current Equity-to-Asset of 0.45 is near median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.61. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.60. Lonza Group's value of 0.45 is 24.4% below this industry median. Based on the distribution chart, Lonza Group ranks #145 out of 210 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lonza Group has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #145 out of 210 companies for Equity-to-Asset. This places Lonza Group in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Lonza Group's value of 0.45 is 24.4% below this benchmark. Historically, Lonza Group's own Equity-to-Asset has ranged from 0.34 to 0.61 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 0.60, Lonza Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lonza Group's current Equity-to-Asset of 0.45 is 24.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lonza Group and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current Equity-to-Asset is 0.45, which is near median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (XSWX:LONN) is currently considered Fairly Valued. The stock's GF Value™ is CHF579.95, compared to a current price of CHF587.80 — trading 1.4% above its estimated fair value. The current Equity-to-Asset is 0.45, which is near median its 10-year median of 0.47 and 24.4% below the Medical Diagnostics & Research industry median of 0.60. Lonza Group's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Lonza Group (XSWX:LONN), the current Equity-to-Asset is 0.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (XSWX:LONN) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be overvalued.
The current stock price of CHF587.80 is trading 1.4% above its estimated GF Value™ of CHF579.95.
GuruFocus considers Lonza Group to be Fairly Valued.
Key valuation signals for XSWX:LONN:
Equity-to-Asset: 0.45 (near median its 10-year median of 0.47)
GF Value™: CHF579.95 vs. price of CHF587.80 (1.4% above fair value)
Industry Position: 24.4% below the Medical Diagnostics & Research median (#145 of 210)
No single metric tells the full story. See the XSWX:LONN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
83GF Score
Get the complete analysis for XSWX:LONN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LONN has been successfully added to your 
